mustang
bio
announces
orphan
drug
designation
treatment
severe
combined
immunodeficiency
xscid
previously
transplanted
patients
worcester
globe
newswire
mustang
bio
mustang
nasdaq
mbio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
today
announced
food
drug
administration
fda
granted
orphan
drug
designation
mustang
lentiviral
gene
therapy
treatment
patients
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
previously
treated
hematopoietic
stem
cell
transplantation
hsct
indicated
august
fda
granted
rare
pediatric
disease
designation
treatment
xscid
previously
treated
patients
hsct
fda
grants
orphan
drug
designation
drugs
biologics
intended
safe
effective
treatment
diagnosis
prevention
rare
diseases
disorders
affect
fewer
people
orphan
drug
designation
provides
certain
incentives
tax
credits
toward
cost
clinical
trials
prescription
drug
user
fee
waivers
product
holding
orphan
drug
designation
receives
first
fda
approval
disease
designation
product
entitled
seven
years
market
exclusivity
independent
intellectual
property
protection
manuel
litchman
president
chief
executive
officer
mustang
said
receipt
orphan
drug
rare
pediatric
disease
designations
fda
treat
xscid
patients
received
prior
hsct
necessary
important
regulatory
milestones
mustang
indicative
significant
unmet
need
devastating
rare
disease
achievements
bring
us
closer
providing
new
potential
treatment
option
patients
families
look
forward
initiating
pivotal
clinical
programs
previously
transplanted
patients
xscid
newly
diagnosed
infants
lentiviral
method
employed
scientists
national
institute
allergy
infectious
diseases
niaid
part
national
institutes
health
jude
children
research
hospital
st
jude
studied
niaid
since
continues
assessed
phase
clinical
trial
xscid
patients
age
two
received
prior
hsct
mustang
expects
file
investigational
new
drug
application
ind
fda
initiate
pivotal
phase
clinical
trial
patient
population
fourth
quarter
additional
phase
clinical
trial
xscid
newly
diagnosed
infants
age
two
ongoing
jude
ucsf
benioff
children
hospital
san
francisco
seattle
children
hospital
product
candidate
trial
designated
may
mustang
submitted
ind
fda
initiate
pivotal
phase
clinical
trial
newly
diagnosed
infants
xscid
two
months
two
years
age
trial
expected
enroll
patients
together
patients
enrolled
current
trial
led
jude
compared
matched
historical
control
patients
undergone
hsct
primary
efficacy
endpoint
survival
initiation
trial
anticipated
fourth
quarter
mustang
targeting
data
trial
second
half
fda
previously
granted
rare
pediatric
disease
orphan
drug
regenerative
medicine
advanced
therapy
designations
treatment
xscid
newly
diagnosed
infants
additionally
european
medicines
agency
granted
advanced
therapy
medicinal
product
classification
severe
combined
immunodeficiency
xscid
severe
combined
immunodeficiency
rare
genetic
disorder
occurs
approximately
per
births
characterized
absence
lack
function
key
immune
cells
resulting
severely
compromised
immune
system
death
year
age
untreated
patients
xscid
natural
killer
cells
although
normal
number
functional
result
xscid
patients
usually
affected
severe
bacterial
viral
fungal
infections
early
life
often
present
interstitial
lung
disease
chronic
diarrhea
failure
thrive
among
patients
receive
hsct
many
unable
establish
adequate
immunity
lose
immunity
time
approximately
patients
receive
hsct
lack
sufficient
immunity
need
lifelong
immunoglobulin
replacement
therapy
specific
genetic
disorder
causes
xscid
mutation
gene
coding
common
gamma
chain
γc
protein
shared
receptors
least
six
interleukins
interleukins
receptors
critical
development
differentiation
immune
cells
gene
coding
γc
known
receptor
gamma
located
xscid
inherited
recessive
pattern
resulting
almost
patients
male
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
xscid
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
sec
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
company
contacts
jaclyn
jaffe
william
begien
mustang
bio
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
media
relations
contact
tony
plohoros
degrees
tplohoros
